Jazz (JAZZ) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
JAZZJazz Pharmaceuticals(JAZZ) Zacks Investment Research·2024-05-02 08:01

Jazz Pharmaceuticals (JAZZ) reported 901.98millioninrevenueforthequarterendedMarch2024,representingayear−over−yearincreaseof1901.98 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 1%. EPS of 2.68 for the same period compares to 3.95ayearago.Thereportedrevenuerepresentsasurpriseof−3.943.95 a year ago. The reported revenue represents a surprise of -3.94% over the Zacks Consensus Estimate of 938.99 million. With the consensus EPS estimate being $4.14, the EPS surprise was -35.27%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations t ...